Combined Radiochemotherapy with Erbitux (Cetuximab) plus Temozolomide in the primary therapy of Glioblastoma Multiforme (GBM) - Phase I/II Trial
- Conditions
- Glioblastoma Multiforme (GBM)
- Registration Number
- EUCTR2005-003911-63-DE
- Lead Sponsor
- niversity of Heidelberg, Frau I. Gürkan, Kaufmännische Direktorin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
Histologically confirmed Glioblastoma Multiforme (GBM)
Age >=18
Age <70
Karnofsky Performance Score >=60
Adequate blood values
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Previous Radiotherapy to the brain
or chemotherapy with temozolomide
Previous therapy with an EGFR-inhibitor
Previous therapy with antibodies
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method